CD8A and non-small cell lung carcinoma: Thommen et al. 24 reported that high baseline levels of PD-1+ CD8+ T cells (>1%, assessed by multiple immunohistochemistry) was correlated with longer OS in advanced NSCLC patients treated with nivolumab.